Abstract:Background: To evaluate the association of potential YAP1/MMP7/CXCL16 axis and tumor infiltrating lymphocytes (TILs) related chemo-response in triple-negative breast cancer (TNBC) patients. Methods: We estimated the messenger RNA (mRNA) expression levels of Yes-associated protein 1 (YAP1), MMP7, and CXCL16 in paired TNBC tumor/para-tumor tissues by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR), and performed statistical analysis according to neoadjuvant chemotherapy (NAC) response. Based on The Cancer Genome Atlas (TCGA) data, we noticed outstanding expression of MMP7/CXCL16 in TNBC cases, as well as associations between MMP7/CXCL16 and HIPPO-YAP1-relevant kinases. We also performed gene set enrichment analysis (GSEA) between MMP7/CXCL16 and YAP1-associated pathways. Western blotting assay was employed to evaluate YAP1/MMP7/CXCL16 expression in vitro and their modulation sequence. Logistic model stepwise regression analysis was used to assess YAP1, MMP7, CXCL16, and TILs as therapeutic predictors. Residual cancer burden (RCB) score was calculated and statistically analyzed according to intensity of these variables, and receiver operating characteristic (ROC) curve also showed their predictive value in NAC response. Recruitment efficacy for CD4+/CD8+ TIL cells (TCGA data) as well as quantified TIL cells density were both explored according to YAP1, MMP7, and CXCL16 expression level. Results: Up-regulation of YAP1/MMP7 and down-regulation of CXCL16 were both significant in TNBC cases with poor NAC response. Inhibition of YAP1 induced down-regulation of MMP7 and up-regulation of CXCL16, whereas inhibition of MMP7 also induced up-regulation of CXCL16. It was also shown that MMP7/CXCL16 was enriched in the YAP1-related pathway. Activation of the YAP1/MMP7/CXCL16 axis obviously affected RCB of TNBC cases. The ROC curve also supported the predictive value of YAP1/MMP7/CXCL16 axis and TILs density in NAC response prospect. The density of TILs, meanwhile, demonstrated a strong link with the YAP1/MMP7/CXCL16 axis. Over expression of YAP1/MMP7 significantly suppressed recruitment of CD4+/CD8+ TILs, while CXCL16 over expression had a beneficial impact on anti-tumor immune. Conclusions: Over expression of causes up-regulation of MMP7 and down-regulation of CXCL16, which suppressed CD4+/CD8+ TILs recruitment and indirectly affected NAC response of TNBC patients.

YAP1-induced RBM24 promotes the tumorigenesis of triple-negative breast cancer through the β-catenin pathway

HJURP Regulates Cell Proliferation and Chemo-Resistance Via YAP1/NDRG1 Transcriptional Axis in Triple-Negative Breast Cancer

Knockdown of TAZ Modifies Triple-Negative Breast Cancer Cell Sensitivity to EGFR Inhibitors by Regulating YAP Expression.

RBM10 regulates the tumorigenic potential of human cancer cells by modulating PPM1B and YBX1 activities

RNA binding protein ZCCHC24 promotes tumorigenicity in triple-negative breast cancer

Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness

SENP3 mediates the deSUMOylation and degradation of YAP1 to regulate the progression of triple-negative breast cancer

RNF181 Modulates Hippo Signaling and Triple Negative Breast Cancer Progression

A Positive Feedback Loop: RAD18-YAP-TGF-β Between Triple-Negative Breast Cancer and Macrophages Regulates Cancer Stemness and Progression

YAP transduction drives triple-negative breast cancer aggressiveness through modulating the EGFR‒AKT axis in patient-derived xenograft cells

RNA N 6 -methyladenosine reader YTHDC1 is essential for TGF-beta-mediated metastasis of triple negative breast cancer

RNA-binding protein complex LIN28/MSI2 enhances cancer stem cell-like properties by modulating Hippo-YAP1 signaling and independently of Let-7

PIWI-interacting RNA-YBX1 inhibits proliferation and metastasis by the MAPK signaling pathway via YBX1 in triple-negative breast cancer

METTL14 Suppresses the Expression of YAP1 and the Stemness of Triple-Negative Breast Cancer.

miR-497 inhibits proliferation and invasion in triple-negative breast cancer cells via YAP1

RBM8A, a new target of TEAD4, promotes breast cancer progression by regulating IGF1R and IRS-2

YB-1 Targeted by miR-509-3-5p Affects Migration and Invasion of Triple‐Negative Breast Cancer by Regulating Cellular Epithelial‐Mesenchymal Transition

DLAT promotes triple-negative breast cancer progression via YAP1 activation

KMT5A-methylated SNIP1 promotes triple-negative breast cancer metastasis by activating YAP signaling

LINC01572 promotes triple‐negative breast cancer progression through EIF4A3‐mediated β‐catenin mRNA nuclear exportation

YAP1/MMP7/CXCL16 axis affects efficacy of neoadjuvant chemotherapy via tumor environment immunosuppression in triple-negative breast cancer